CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin is the gold-standard GH optimisation stack in research protocols. CJC-1295 (without DAC) acts as the GHRH analogue that amplifies GH synthesis capacity in pituitary somatotrophs, while Ipamorelin provides the GHSR-1a-mediated release trigger. Their combined action produces GH pulses 3–5× larger than either compound alone, with Ipamorelin's clean hormonal profile keeping cortisol and prolactin unaffected.
Stack Components
This blend combines 2 research peptides with complementary mechanisms designed to produce synergistic outcomes.
Synergy Rationale
CJC-1295 and Ipamorelin work through completely different receptors, which is why their combination is synergistic rather than merely additive. CJC-1295 activates GHRH receptors, signalling the somatotroph cells to synthesise more GH and increasing the "ready pool" available for release. This primes the pituitary but does not trigger the release pulse itself.
Ipamorelin activates the ghrelin receptor (GHSR-1a), which does trigger the release pulse. When both are present simultaneously, Ipamorelin releases a much larger pulse because CJC-1295 has already enlarged the pool it can release from. This GHRH + GHRP synergy was identified in early GH research and is the physiological basis for the combination protocol.
The resulting GH pulse closely mimics the natural nocturnal GH surge — pulsatile, large amplitude, and cleanly resolved — rather than creating the sustained supraphysiological GH levels associated with exogenous hGH use.
Combined Mechanism of Action
CJC-1295 binds GHRH receptors on anterior pituitary somatotrophs. Its modified amino acid substitutions resist DPP-IV enzymatic degradation, extending biological activity to ~30 minutes versus native GHRH's 10-minute window. This drives upregulation of GH synthesis genes and fills the releasable GH pool.
Ipamorelin activates GHSR-1a (ghrelin receptor) with high selectivity. Unlike GHRP-2 or GHRP-6, it does not co-stimulate ACTH/cortisol or prolactin pathways at research doses, producing a clean GH pulse. It also suppresses somatostatin release in the hypothalamus — the GH-inhibiting hormone — further amplifying the net release.
Co-administration produces synergistic GH pulse amplification: GHRH receptor priming (CJC-1295) + GHSR-1a trigger (Ipamorelin) + somatostatin suppression (Ipamorelin) = maximum pulsatile GH output within the body's natural regulatory range.
Research Evidence
Both compounds have individual clinical research records. The combination protocol is standard practice in GH deficiency research and anti-aging medicine. Phase 1 data on CJC-1295 and published Ipamorelin selectivity studies both inform understanding of this stack.
CJC-1295 Dose-Dependently Elevates GH and IGF-1 in Healthy Adults
CJC-1295 (with DAC) produced 2–10× mean GH increase and 1.5–3× IGF-1 elevation. The without-DAC form produces similar amplitude in a single pulse rather than sustained elevation.
Ipamorelin Does Not Elevate Cortisol, ACTH, or Prolactin
At doses producing maximal GH response, Ipamorelin produced statistically insignificant changes in cortisol, ACTH, and prolactin — establishing its clean hormonal profile advantage over GHRP-2 and GHRP-6.
Component Dosing Protocol
CJC-1295 (no DAC) and Ipamorelin are typically combined in the same syringe at a 1:1 mcg ratio and injected together. Bedtime dosing maximises the natural nocturnal GH pulse. Fasting for 2+ hours before injection significantly increases GH pulse amplitude.
Safety Considerations
Reported Side Effects
- Water retention (wrists, ankles)
- Tingling in hands/feet (carpal tunnel-like, usually resolves)
- Headache (first week)
- Increased hunger (mild)
- Fatigue (initial week)
Contraindications
- Active malignancy
- Uncontrolled diabetes (GH increases insulin resistance acutely)
- Hypothyroidism (correct first — GH axis requires normal thyroid)
- Pregnancy
- GH-sensitive pituitary pathology
Frequently Asked Questions
Can CJC-1295 and Ipamorelin be mixed in the same syringe?
Yes — this is standard practice. Both are stable peptides in bacteriostatic water and there is no known chemical incompatibility. Mixing them 1:1 in the same syringe allows a single injection. Prepare the mixture fresh before each injection or mix a batch and store refrigerated, using within 4 weeks.
What ratio of CJC-1295 to Ipamorelin should I use?
1:1 by mcg is the standard research ratio (e.g., 100 mcg CJC-1295 + 100 mcg Ipamorelin, or 200/200). Some protocols use higher Ipamorelin (e.g., 100 CJC + 200 Ipamorelin) to emphasise the release trigger. There is no definitive human data establishing an optimal ratio.
How is this different from using exogenous HGH?
This stack stimulates the pituitary to produce its own GH — it does not introduce exogenous growth hormone. Effects are dose-regulated by the body's natural somatostatin feedback, producing physiological pulses rather than constant supraphysiological levels. This approach preserves long-term pituitary responsiveness and avoids shutting down natural GH production.
What results should I expect from CJC-1295 + Ipamorelin?
Commonly reported research outcomes (over 12–16 weeks) include: improved sleep depth and quality (often the first benefit noted), reduced body fat particularly in visceral/abdominal areas, increased lean muscle tissue, improved skin texture and thickness, faster recovery from training, and elevated energy. Results are gradual — body composition changes typically become evident at 8–12 weeks.
Should I monitor IGF-1 levels on this protocol?
IGF-1 monitoring is strongly recommended. Baseline IGF-1 before starting, then at 8 weeks and on completion. IGF-1 should remain within the upper range of normal (approximately 200–300 ng/mL for adults) — excessive elevation is associated with accelerated cell proliferation and insulin resistance. Monitoring allows dose adjustment to achieve the target GH effect without overshooting.
Key Research References
- Alba M et al. (2006). Once-monthly administration of CJC-1295 to healthy adults. J Clin Endocrinol Metab.
- Johansen PB et al. (1999). Ipamorelin: a new growth-hormone-releasing peptide. Growth Horm IGF Res.
Explore more peptide combination stacks
Browse All Blends →